Revenues grew 15.6% to Rs 10,172 crore due to price hikes taken across product range in June quarter
New order wins should help raise, diversify revenue base; rising profit to drive earnings, stock
Company maintains operating-profit margin forecast at 16-18 per cent for FY17
British drug maker GSK's global CEO Sir Andrew Witty will step down next March after eight years
A better performance in the second half of this financial year could have a positive impact on the stock
Results in line with estimates, but rise in lead prices and competition could weigh on profit
Settlement with Mylan and strong forecast for the second half of FY17 are positives
Higher raw material costs and pricing pressures might pose risks to margin improvement
Muted September quarter additions and Arpu pressures are an overhang
Fills spectrum gap in key markets; Q2 disappoints; likely price wars could hurt financials
RJio launch and data expansion are expected to improve prospects but there could be a few bumps on the way
RJio launch and data expansion are expected to improve prospects but there could be a few bumps on the way
Remaining businesses will need to generate healthy cash flow for servicing the residual debt
Change in business focus and lower capex are positives; these will boost the company's stock valuations
Sales growth in Brazil and India, as well as margin gains from developed markets, should result in strong earnings over FY17-19
Idea, Vodafone have increased their spectrum holdings, as they are lagging Bharti in 3G/4G presence
Company hopes new launches will boost its domestic sales
Given the company's past track record, growth prospects and reasonably valuations, long-term investors can subscribe to the offer
There is little doubt about the strength of the company's biosimilar portfolio but upsides are a couple of years away
A timely call on a steady decline in interest rates helped HDFC Mutual Fund's Anil Bamboli reap the gains